ArticleBiologics : targets & therapy2009
The old and new therapeutic approaches to the treatment of giardiasis: where are we?
Article in Biologics : targets & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of randomized clinical trials.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Systematic Review of Diagnostic Approaches for Human Giardiasis: Unveiling Optimal Strategies.Diagnostics (Basel, Switzerland) · 2024Review
- The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children.Microorganisms · 2023Review
- Probiotics in the management of Giardia duodenalis: an update on potential mechanisms and outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Brazilian Protocol for Sexually Transmitted Infections, 2020: sexually transmitted enteric infections.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Structure-based identification of a potential non-catalytic binding site for rational drug design in the fructose 1,6-biphosphate aldolase from Giardia lamblia.Scientific reports · 2019Article
- Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum.PLoS neglected tropical diseases · 2018Article
- Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential.International journal for parasitology. Drugs and drug resistance · 2017Article
- Molecular Characterization of Cryptosporidium Species and Giardia duodenalis from Symptomatic Cambodian Children.PLoS neglected tropical diseases · 2016Article
- An antioxidant response is involved in resistance of Giardia duodenalis to albendazole.Frontiers in microbiology · 2015Article
- Article
- Giardia fatty acyl-CoA synthetases as potential drug targets.Frontiers in microbiology · 2015Article
- Epidemiology and geographical distribution of enteric protozoan infections in sydney, australia.Journal of public health research · 2014Article
- Article
- Enteric protozoa in the developed world: a public health perspective.Clinical microbiology reviews · 2012Review
- Antiparasitic therapy.Mayo Clinic proceedings · 2011Review
- High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.Antimicrobial agents and chemotherapy · 2011Article
- Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases.Gut microbesReview
- Therapeutic Effect of Chitosan Nanoparticles and Metronidazole in Treatment of Experimentally Giardiasis Infected Hamsters.Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giardia lamblia is the causative agent of giardiasis, one of the most common parasitic infections of the human intestinal tract. This disease most frequently affects children causing abdominal pain, nausea, vomiting, acute or chronic diarrhea, and malabsorption syndrome. In undernourished children, giardiasis is a determining factor in retarded physical and mental development. Antigiardial chemotherapy focuses on the trophozoite stage. Metronidazole and other nitroimidazoles have been used for decades as the therapy of choice against giardiasis. In recent years many other drugs have been proposed for the treatment of giardiasis. Therefore, several synthetic and natural substances have been tested in search of new giardicidal compounds. This study is a review of drugs used in in vitro and in vivo tests, and also drugs tested in clinical trials (nonrandomized and randomized).
Indexed as
Identifiers
19707415PMC2726062W2084853343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.